Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on September 16 a proposed $1.05 billion offering of convertible senior notes due October 1, 2033. The plan includes an expected option for initial purchasers to buy another $150 million. The interest rate and initial conversion terms were to be determined at pricing. Halozyme Therapeutics, Inc. (NASDAQ:HALO) intends to use [...]